Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L , Ajani JA
It subsequently suppresses the hepatic LPSTLR4NF-B signaling pathway, reducing inflammation and fibrotic progression
et al., Drug Design, Development and Therapy Bottom line: IGF-1 LR3 is not a hormone disruptor, and it carries very little risk of masculinizing effects
Such work would illuminate how interventions such as semaglutide rewire metabolic networks across the liver and extrahepatic organs